Generic Product News

Published Online: Monday, April 14, 2014
Follow Pharmacy_Times:

Clobetasol Propionate Foam, 0.05%
Marketed by:
Renaissance Pharma
Compare to: Olux Foam (Prestium Pharma, Inc)
Indication: Renaissance Pharma introduces Clobetasol Propionate Foam, 0.05%, a generic equivalent to Stiefel Laboratories’ Olux Foam. It is indicated for the short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatosis of the scalp, and for short-term treatment of mild to moderate plaque-type psoriasis on nonscalp regions, excluding the face and intertriginous areas. It can be applied twice per day, once in the morning and once at night.
Dosage Form: Foam: 50 and 100 g
For More Information: www.RenaissancePharmaInc.com



Moxifloxacin Hydrochloride Tablets
Marketed by:
Teva Pharmaceuticals
Compare to: Avelox Tablets (Bayer HealthCare Pharmaceuticals, Inc)
Indication: Teva Pharmaceuticals announces the introduction and availability of moxifloxacin hydrochloride tablets, an AB-rated equivalent to Avelox Tablets. It is a fluoroquinolone antibacterial indicated for treating infections caused by designated susceptible bacteria in adults 18 years and older. The recommended dose is 400 mg once a day. The duration of therapy varies by infection type; further information can be found in the full prescribing information.
Dosage Form: Tablets: 400 mg
For More Information: www.TevaGenerics.com



Prochlorperazine Edisylate Injection
Marketed by:
Heritage Pharmaceuticals, Inc
Compare to: Compazine (GlaxoSmithKline; discontinued)
Indication: Heritage Pharmaceuticals Inc announces the immediate availability of prochlorperazine edisylate injection in the mg/mL strength. It is the AP-rated generic equivalent to the former brand Compazine. Prochlorperazine edisylate injecton is indicated for the treatment of severe nausea and vomiting and for the treatment of schizophrenia. It should be administered intramuscularly or intravenously; subcutaneous administration is not advisable due to local irritation.
Dosage Form: Injectable vial: 5 mg/mL
For More Information: www.heritagepharma.com



Doxercalciferol Capsules
Marketed by:
Roxane Laboratories
Compare to: Hectorol (Genzyme Corporation)
Indication: Roxane Laboratories announces the availability of doxercalciferol capsules, an AB-rated equivalent to Genzyme’s Hectorol capsules. They are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, and for the treatment of secondary hyperparathyroidism in patients with stage-3 or -4 chronic kidney disease. The recommended initial dose of doxercalciferol capsules is 10 mcg administered 3 times weekly at dialysis, approximately every other day.
Dosage Form: Capsules: 0.5, 1, and 2.5 mcg
For More Information: www.roxane.com

Related Articles
Teva Pharmaceutical Industries Ltd. announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States.
GSK has announced the winners of its second Discovery Fast Track Challenge - a program designed to combine the expertise of academic researchers with that of drug discovery scientists at GSK, to accelerate the search for new medicines.
Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Exforge HCT Tablets in the United States.
Latest Issues
$auto_registration$